Syntekabio (KOSDAQ: 226330), an AI-based drug development company, has announced a pioneering initiative aimed at minimizing risk, saving time and costs, and boosting the success rates for companies involved in developing novel therapies. The 'Develop Now, Pay Later' offer is Syntekabio's newest strategy to invest in its clients' success without requiring any upfront costs.
This innovative model allows pharmaceutical and biotechnology companies to test the validity of their target protein of interest. If the project demonstrates viability, Syntekabio then utilizes its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher® technology platform, to deliver hits, optimized leads, and IND-enabled candidates. This approach aims to provide clients with first-in-class or best-in-class compounds quickly.
According to Jongsun Jung, PhD, CEO of Syntekabio, “We want our clients to achieve their goal of bringing safer and more effective therapies to patients. Thus, our mission at Syntekabio is to deliver to our clients first-in-class or best-in-class compounds, fast. We strongly believe in the capability of our technology and so, to further invest in our clients’ success, we have introduced our Develop Now, Pay Later model to support groundbreaking drug development work and reduce the risk for our clients at the outset.”
Syntekabio is committed to optimizing and lowering the risk in drug discovery. Clients can benefit from a complimentary feasibility study to determine the viability of their project. The next step involves submitting any target protein for analysis through the STB LaunchPad program, with no upfront fees required. Payment is only necessary once the agreed-upon validated results are achieved.
Syntekabio’s AI technology has access to over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets, covering more than 70% of human diseases. This advanced technology is supported by Syntekabio’s AI Bio-Supercom Center, which boasts an extensive infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs that fuel the company’s algorithms. Additionally, Syntekabio offers a comprehensive suite of proprietary tools designed to accelerate the drug discovery and development process.
For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here.
